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We have described that Galanin N-terminal fragment (1-15) [GAL(1-15)] is associated 
with depressive effects and also modulates the antidepressant effects induced by the 
5-HT1A receptor (5-HT1AR) agonist 8-OH-DPAT in the forced swimming test (FST). 
Importantly, the mechanism underlying this action involved interactions at the receptor 
level in the plasma membrane with changes also at the transcriptional level. Thus, 
GAL(1–15) affected the binding characteristics as well as the mRNA levels of 5-HT1AR 
in the dorsal hippocampus and dorsal raphe (DR). 
Recently, we observed that GAL(1-15) enhanced the antidepressant-like effects 
induced by Fluoxetine (FLX) in the FST. In view of this, we have studied whether the 
effects of GAL(1–15) on FLX action were mediated via 5-HT1AR, analyzing the effect 
of the 5-HT1AR antagonist WAY100635 in the GAL(1-15)-mediated effect in the FST. 
We have also determined the binding characteristics and mRNA levels of 5-HT1AR in 
the DR and dorsal hippocampus after GAL(1-15)-FLX administration.  
 
To study if the effects of GAL(1-15) on FLX action were mediated via the 5HT1AR, 
groups of rats (n=6-8 rats per groups) received three subcutaneous injections (sc) of 
FLX(10mg/kg) and 15 minutes before the FST a single intracerebroventricular injection 
(icv) of GAL(1-15) (1nmol) and 5HT1AR antagonist WAY100635(6nmol) icv alone or in 
combination. 
In the second set of experiments, we analyzed the effects of the three injections of sc 
FLX or Vehicle and a single icv injection of GAL(1-15) or aCSF and sacrified 30 min 
later to analyze the binding characteristics of the 5-HT1AR agonist [H3]-8-OH-DPAT 
and 5-HT1A mRNA levels in sections of the DR and Dorsal Hippocampus, specifically 
in the Ammon’s horn 1 (CA1) and Dentate Gyrus (DG).  
 
The results confirmed that the 5HT1AR participates in this interaction as the 5HT1AR 
antagonist WAY100635 (6nmol) significantly blocked the reduction in immobility time 
(p<0.05), and the increase in swimming time (p<0.01) induced by the coadministration 
of icv GAL(1-15) and the three injections of sc FLX(10mg/kg) in the FST. 
The coadministration of the three sc injections of FLX(10mg/Kg) and a single icv 
injection of GAL(1-15)(1nmol) produced a significant increase in the 5HT1AR mRNA 
levels in CA1 (p<0.05) and DG (p<0.05) of the dorsal hippocampus compared to 
controls and single treatments. This effect was not observed in the DR. 
In the autoradiographic experiments, the coadministration of the three injections of sc 
FLX(10mg/Kg) and a single icv injection of GAL(1-15)(1nmol) produced a significant 
decrease in the Kd value (p<0.01) and in the Bmax value (p<0.05) of the agonist 
radioligand [3H]-8-OH-DPAT in the DG of the dorsal Hippocampus compared to 
FLX(10mg/Kg) alone. 
These effects were not observed in the CA1 area of the Hippocampus or in the DR. 
These results indicate that 5HT1AR participates in the GAL(1-15)/FLX interactions in 
the FST. The mechanism underlying GAL(1-15)/FLX interactions affected the binding 
characteristics as well as the mRNA levels of 5-HT1AR specifically in the dorsal 
hippocampus while leaving unaffected mRNA levels and affinity and binding sites of 
this receptor in the DR. The target for GAL(1-15) may mainly be 5-HT1AR-GALR1-
GALR2 heteroreceptor complexes located postjunctionally in the dorsal hippocampus. 
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